LUMO is expected to report earnings to fall 20.47% to -73 cents per share on November 18
Q3'24
Est.
$-0.74
Q2'24
Beat
by $0.24
Q1'24
Missed
by $0.30
Q4'23
Missed
by $3.04
Q3'23
Beat
by $0.11
The last earnings report on August 01 showed earnings per share of -93 cents, beating the estimate of -116 cents. With 101.61K shares outstanding, the current market capitalization sits at 37.45M.
a clinical-stage biopharmaceutical company, which engages in the development of therapeutics for the treatment of Pediatric Growth Hormone Deficiency (PGHD)